Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19626358 | 1.00 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3HTR2CHTR2A | |
| SCHEMBL17724996 | 1.00 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3HTR2CHTR2A | |
| SCHEMBL17713123 | 1.00 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3HTR2CHTR2A | |
| SCHEMBL17725407 | 1.00 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3HTR2CHTR2A | |
| SCHEMBL21418962 | 1.00 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3HTR2CHTR2A | |
| SCHEMBL23466001 | 0.75 | HTR2A (0.44) | HTR2A | |
| SCHEMBL19629563 | 0.75 | HTR2A (0.44) | HTR2A | |
| SCHEMBL17725107 | 0.75 | HTR2A (0.44) | HTR2A | |
| SCHEMBL21418955 | 0.75 | HTR2A (0.44) | HTR2A | |
| SCHEMBL19629494 | 0.75 | HTR2A (0.44) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| US-20190300514-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | INDIVIOR INC. | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | DRD3, DRD2, DRD4 | SLC6A2 106/4885SLC6A4 181/4885SLC6A3 5/4885 |
| US-20190300514-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | DRD3, DRD2, DRD4 | SLC6A2 106/4885SLC6A4 181/4885SLC6A3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.